# PT-141 Effects, Side Effects, and Cautions: What the Evidence Shows > PT-141 (bremelanotide) effects from the trials and the label: improved sexual desire in women with HSDD, nausea, flushing, blood-pressure cautions, and what is off-label. What the trials and the approved label actually recorded — benefits, the common side effects, and the cited safety cautions. ## Start here PT-141 (bremelanotide) is the rare desire drug whose effects were measured in large human trials, so the picture here is unusually solid. In premenopausal women with HSDD — low sexual desire that causes distress — the approved use improved desire and lowered desire-related distress over 24 weeks [3], and the gains held for up to a year [4]. The trade-off is tolerability: nausea is common, flushing and headache happen, and there is a short-lived rise in blood pressure after each dose [4][7]. Below we separate three things people often blur together: what the studies measured (cited evidence), what the research-use community reports (anecdote, clearly labeled), and the cited safety cautions. Uses in men, in postmenopausal women, or for performance are off-label or investigational, and we mark them so. No dose is recommended to anyone on this page. ## What the studies measured In the RECONNECT Phase 3 program (1,267 premenopausal women with HSDD), bremelanotide 1.75 mg under the skin as needed improved sexual desire (FSFI-desire +0.35, P<.001) and reduced the distress tied to low desire (FSDS-DAO item 13 −0.33, P<.001) versus placebo over 24 weeks [3]. Over a 52-week extension in 684 women, those improvements were sustained and no new safety signals appeared [4]. A brain-imaging study of 31 women found the central mechanism in action: desire rose for up to 24 hours and brain processing of erotic stimuli changed [5]. In preclinical work, the same compound selectively increased appetitive (desire-driven) sexual behavior in female rats without changing reflexes or general movement [2], and produced dose-dependent erectile activity in male rats, primates, and men with erectile dysfunction [1]. A 2025 pooled meta-analysis reported bremelanotide improved the total Female Sexual Function Index plus the desire and arousal subscales across trials [15]. ## PT-141 for women The approved effect is in women: premenopausal women with acquired, generalized HSDD [7]. The desire and distress improvements in RECONNECT are the basis for approval [3], and a separate scanner study links the effect to changed central brain processing rather than to anything peripheral [5]. The effect sizes are statistically significant; some independent analysts argue they are small and debate how meaningful they are in daily life [3]. Postmenopausal use is not approved [7]. ## PT-141 for men Use in men is off-label and investigational. Early dose-escalation studies in men with erectile dysfunction did show a dose-dependent erectile response, with a statistically significant effect at higher doses in the intranasal work [1]. A manufacturer started a Phase 2 study in 2024 combining bremelanotide with a PDE-5 inhibitor (an erection medicine that works on blood vessels) for male erectile dysfunction [14]. None of this is FDA-approved, and a 2008 erectile-dysfunction salvage study by Safarinejad and Hosseini received a 2023 Expression of Concern — a formal notice that its integrity is in question — so its findings should be treated as disputed [1]. ## What people report These are effects described in research-use communities — anecdotal, not clinical evidence, not verified by controlled trials, and never tied to a dose here. Frequently described upsides track the trial picture: a rise in sexual desire and arousal that is felt rather than mechanical, often hours after use. Frequently described downsides also track the label: nausea is the most common complaint, sometimes with flushing or headache, and some people report temporary skin or gum darkening with repeated use [7]. Reports of "performance" or testosterone effects are not supported by the mechanism — PT-141 does not act through the hormone axis and does not raise testosterone [1]. Treat all of the above as community impression, not findings; the cited evidence is in the section above and on [the research page](/research). ## PT-141 side effects The PT-141 side effects in long-term human use are well characterized for the approved population. Over 52 weeks, the most common drug-related events were nausea (40.4%), flushing (20.6%), and headache (12.0%) [4]. Nausea is a notable reason people stop, and timing and dose strategy have been studied as ways to limit it [4]. The label also documents a transient rise in blood pressure after dosing [7], and the NIH LiverTox monograph notes mild serum-enzyme elevations and rare cases of clinically apparent acute liver injury [10]. ## Safety & cautions **Blood pressure and cardiovascular disease.** The approved label warns of a transient blood-pressure increase after each dose and contraindicates use in uncontrolled high blood pressure or known cardiovascular disease [7]. This is a documented label warning, not a theoretical one. **Nausea and tolerability.** Nausea affected roughly 40% of long-term users and is the main tolerability issue and a driver of discontinuation [4]. **Skin and tissue darkening.** Hyperpigmentation of the face, gums, and breasts is reported with repeated frequent dosing and is attributed to MC1R activation (a melanocortin receptor in pigment cells) [7]. Mechanistically, more frequent dosing carries more of this risk. **Liver.** The LiverTox monograph notes mild enzyme elevations and rare instances of acute liver injury with this melanocortin agonist [10]. **Unregulated "research chemical" supply.** Material sold as PT-141 outside the pharmaceutical framework has no oversight of identity, purity, or concentration [7]. This is a theoretical-but-real caution: what is in such a vial is unverified. **Off-label and investigational uses.** Appetite and body-weight effects seen with high-frequency dosing reflect MC4R activity in appetite circuits and are a pharmacological consideration, not an approved use [7]. None of the male, postmenopausal, or performance uses are approved [7]. --- A plain-clinical reading room on bremelanotide — the trials, the label, and how access works, with no dose recommended to anyone.